PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2006138181) SELF-BUFFERING PROTEIN FORMULATIONS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2006/138181 International Application No.: PCT/US2006/022599
Publication Date: 28.12.2006 International Filing Date: 08.06.2006
IPC:
A61K 39/395 (2006.01) ,C12P 21/08 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
P
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21
Preparation of peptides or proteins
08
Monoclonal antibodies
Applicants:
AMGEN INC. [US/US]; M/S 28-2-C One Amgen Center Drive Thousand Oaks, CA 91320-1799, US (AllExceptUS)
GOKARN, Yatin, R. [IN/US]; US (UsOnly)
KRAS, Eva [US/US]; US (UsOnly)
REMMELE, Richard, Louis, Jr. [US/US]; US (UsOnly)
BREMS, David, N. [US/US]; US (UsOnly)
HERSHENSON, Susan, Irene [US/US]; US (UsOnly)
Inventors:
GOKARN, Yatin, R.; US
KRAS, Eva; US
REMMELE, Richard, Louis, Jr.; US
BREMS, David, N.; US
HERSHENSON, Susan, Irene; US
Agent:
REINECKE, Raz; Amgen Inc. Mail Stop 28-2-C One Amgen Center Drive Thousand Oaks, CA 91320-1799, US
Priority Data:
60/690,58214.06.2005US
Title (EN) SELF-BUFFERING PROTEIN FORMULATIONS
(FR) PREPARATIONS DE PROTEINES A TAMPONNAGE SPONTANE
Abstract:
(EN) The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use. The invention in these and other respects can be productively applied to a wide variety of proteins and is particularly useful for making and using self-buffering formulations of pharmaceutical proteins for veterinary and medical use, especially, in particular, for the treatment of diseases in human subjects.
(FR) L'invention concerne, entre autres, des préparations de protéines à tamponnage spontané. L'invention concerne en particulier des préparations de protéines pharmaceutiques à tamponnage spontané qui sont appropriées pour un usage en médecine vétérinaire et humaine. Les préparations de protéines à tamponnage spontané sont sensiblement dépourvues d'autres tampons, maintiennent de manière stable le pH pour des durées prolongées impliquées dans la distribution et le stockage de protéines pharmaceutiques à usage en médecine vétérinaire et humaine. L'invention concerne également des méthodes de conception, de production et d'utilisation de la préparation. En plus d'autres avantages, les préparations évitent les désavantages associés aux tampons traditionnellement utilisés dans les préparations courantes de protéines à usage pharmaceutique. L'invention peut être appliquée de manière productive à une large variété de protéines et est particulièrement utile pour la production et l'utilisation de préparations à tamponnage spontané de protéines pharmaceutiques à usage vétérinaire et médical, notamment, en particulier, pour le traitement de maladies chez des sujets humains.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
MXMX/a/2007/015476KR1020080031684IL188102SG162788EP1909831ZA2008/00338
JP2008543839US20080311078BRPI0611901JP2013047261CN101217979CA2610839
EA200800050JP2016053061AU2006259664AU2012272950AU2015242973AU2017202889
IN5286/CHENP/2007JP2018048196EP3351269